FAQ: Nutriband's Partnership with Brand Institute for AVERSA FENTANYL Brand Development
Summary
Nutriband Inc. has partnered with Brand Institute to develop the global brand identity for AVERSA FENTANYL, an abuse-deterrent fentanyl patch that could become the world's first abuse-deterrent opioid patch. This collaboration leverages Brand Institute's expertise in pharmaceutical branding and regulatory approval to advance a product designed to prevent opioid misuse and accidental exposure.
What is the main announcement in this content?
Nutriband Inc. has announced that its subsidiary 4P Therapeutics has signed an agreement with Brand Institute to create the worldwide commercial brand name and visual identity for AVERSA FENTANYL, the company’s lead product using AVERSA abuse-deterrent transdermal technology.
What is AVERSA FENTANYL and why is it significant?
AVERSA FENTANYL is an abuse-deterrent opioid patch that could become the world’s first abuse-deterrent opioid patch. It’s designed to deter misuse and reduce accidental opioid exposure using Nutriband’s proprietary AVERSA technology.
Who is Brand Institute and what role are they playing?
Brand Institute is a global leader in pharmaceutical brand name and identity development with a 75% share of global drug name approvals and 87% of FDA-approved names in 2024. They will lead the branding initiative alongside their regulatory subsidiary, Drug Safety Institute.
What is the AVERSA technology and how does it work?
AVERSA is an abuse-deterrent transdermal technology that can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. It’s specifically designed to deter opioid misuse.
What is Nutriband Inc.’s primary business focus?
Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products, with their lead product being the abuse-deterrent fentanyl patch incorporating AVERSA technology.
Where can investors find more information about Nutriband?
The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB, and the company’s website is www.nutriband.com.
What regulatory expertise does Brand Institute bring to this partnership?
Brand Institute’s regulatory subsidiary, Drug Safety Institute, is staffed by former FDA, EMA, Health Canada, USAN, and WHO officials, providing significant regulatory expertise for the global branding initiative.
How does this partnership benefit the development of AVERSA FENTANYL?
The partnership leverages Brand Institute’s proven track record in pharmaceutical branding and regulatory approval processes, which should help accelerate the global commercial development and regulatory acceptance of AVERSA FENTANYL as an abuse-deterrent opioid product.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 249359